Paysign Inc

Paysign Inc (PAYS) Stock Analysis

$15.600

+0.452 (+2.90%)At close

Loading chart…
High
15.620
Open
15.000
VWAP
15.38
Volume
747.06K
Mkt Cap
212.44M
Low
14.930
Amount
11.49M
EV/EBITDA, TTM
18.04

Paysign, Inc. is a provider of prepaid card programs, patient affordability offerings, digital banking services and integrated payment processing designed for businesses, consumers and government institutions. The Company’s payment solutions are utilized by its corporate customers to increase customer loyalty, increase patient adherence rates, reduce administration costs and streamline operations. It markets its prepaid card solutions under its Paysign brand. Its end-to-end technologies securely enable digital payout solutions and facilitate the distribution of funds for donor compensation, copay assistance, employee rewards, travel expenses, per diem, reimbursements, rebates, and countless other exchanges of value. It operates on a payments platform with fintech capabilities that can be seamlessly integrated with its clients’ systems. It offers donor engagement app, which integrates seamlessly with existing donor management systems, delivering immediate value to plasma centers.

paysign.com

AI analysis of Paysign Inc (PAYS)

Buy

Paysign Inc is a good buy right now due to its strong recent performance, with a current price of $15.37 and a year-to-date change of +209.88%. The company reported a Q2 EPS of $0.11, exceeding expectations by $0.05, and raised its full-year revenue guidance to between $114 million and $117 million, showcasing robust growth potential. However, the main risk is the high forward P/E ratio of 29.59, which suggests that the stock may be overvalued if growth slows.

Valuation Metrics

The current forward P/E ratio for Paysign Inc (PAYS) is 29.59, compared to its 5-year average forward P/E of 56.17.

Forward P/E

Fair
5Y Average P/E
56.17
Current P/E
29.59
Overvalued
202.14
Undervalued
-89.80

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
17.20
Current EV/EBITDA
18.04
Overvalued
22.37
Undervalued
12.02

Forward P/S

Strongly Overvalued
5Y Average P/S
3.08
Current P/S
6.54
Overvalued
4.01
Undervalued
2.14

Alphio AI Price Scenarios for PAYS

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%PAYS

$5.83

Scenario price

B

Base

Base · 50%PAYS

$5.22

Scenario price

B

Bear

Bear · 25%PAYS

$3.85

Scenario price

Whales holding PAYS

P

Punch & Associates Investment Management, Inc.

+ HoldingPAYS

-5.38%

3M Return

Events Timeline

2026-08-05 (ET)

17:00:00

Sees Q3 Revenue of $28.5M-$30M

17:00:00

Paysign Reports Q2 Revenue of $28.25M

17:00:00

Raises FY26 Revenue Outlook to $114M-$117M

2026-05-13 (ET)

10:40:00

Sees Q2 Revenue of $26.2M-$26.7M

10:40:00

Paysign Sees 2026 Revenue Guidance of $106.5M-$110.5M

News

PAYS FAQ — answered by Alphio AI

Paysign, Inc. is a provider of prepaid card programs, patient affordability offerings, digital banking services and integrated payment processing designed for businesses, consumers and government institutions. The Company’s payment solutions are utilized by its corporate customers to increase customer loyalty, increase patient adherence rates, reduce administration costs and streamline operations. It markets its prepaid card solutions under its Paysign brand. Its end-to-end technologies securely enable digital payout solutions and facilitate the distribution of funds for donor compensation, copay assistance, employee rewards, travel expenses, per diem, reimbursements, rebates, and countless other exchanges of value. It operates on a payments platform with fintech capabilities that can be seamlessly integrated with its clients’ systems. It offers donor engagement app, which integrates seamlessly with existing donor management systems, delivering immediate value to plasma centers. It operates in the Industrials sector (SERVICES-BUSINESS SERVICES, NEC industry).

Paysign Inc is a good buy right now due to its strong recent performance, with a current price of $15.37 and a year-to-date change of +209.88%. The company reported a Q2 EPS of $0.11, exceeding expectations by $0.05, and raised its full-year revenue guidance to between $114 million and $117 million, showcasing robust growth potential. However, the main risk is the high forward P/E ratio of 29.59, which suggests that the stock may be overvalued if growth slows.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading